Inmune Bio ( (INMB) ) has shared an announcement.
INmune Bio Inc. has released preliminary results from a Phase I/II trial of its INKmune therapy, which targets metastatic, castration-resistant prostate cancer by activating NK cells. The trial, which began in March 2025, has shown promising safety and immunologic efficacy, with no serious adverse effects reported after 29 infusions across three dosage levels. The trial aims to determine the effective dose and assess both short- and long-term safety, as well as the therapy’s ability to control tumor burden. The results could enhance INmune Bio’s position in the cancer immunotherapy market and provide significant implications for stakeholders, particularly in terms of advancing cancer treatment options.
More about Inmune Bio
INmune Bio Inc. operates in the biotechnology industry, focusing on developing therapies that harness the power of the immune system to treat cancer and other diseases. The company’s primary product, INKmune, is designed to activate natural killer (NK) cells in vivo to target and destroy cancer cells, with a particular focus on metastatic, castration-resistant prostate cancer.
YTD Price Performance: 62.88%
Average Trading Volume: 379,059
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $178M
Find detailed analytics on INMB stock on TipRanks’ Stock Analysis page.